Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists

Igor Stojkov, Annette Conrads-Frank, Ursula Rochau, Karin A. Koinig, Marjan Arvandi, Sibylle Puntscher, Corine van Marrewijk, Pierre Fenaux, Argiris Symeonidis, Fatiha Chermat, Hege Garelius, David Bowen, Moshe Mittelman, Elvira Mora, Theo de Witte, Fabio Efficace, Uwe Siebert, Reinhard Stauder*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Patient-reported outcomes (PROs) are relevant and valuable end points in the care of patients with myelodysplastic syndromes (MDS). However, a consensus-based selection of PROs for MDS, derived by both patients and hematologists, is lacking. We aimed to develop a core set of PROs for patients with MDS as part of the prospective European LeukemiaNet MDS (EUMDS) Registry. According to international guidelines, candidate PROs were identified from a comprehensive literature search of MDS studies. Overall, 40 PROs were selected and evaluated in a two-round Delphi survey by 40 patients with MDS and 38 hematologists in the first round and 38 patients and 32 hematologists in the second round. Based on an agreement scale and predefined inclusion criteria, both patients and hematologists selected “general quality of life” as a core PRO. Hematologists also selected “transfusion-dependency burden” and “ability to work/activities of daily living” as core PROs. The second Delphi round increased PRO rating agreements. Statistically significant rating differences between patients and hematologists were observed for 28 PROs (Mann-Whitney U test; P, .05) in the first round and for 19 PROs in the second round, with “disease knowledge” and “confidence in health care services” rated notably higher by patients. The overall mean PRO ratings correlation between the 2 groups was moderate (Spearman’s rank correlation coefficient 5 0.5; P, .05). This first consensus on a core set of PROs jointly developed by patients and hematologists forms the basis for patient-centered care in daily practice and clinical research.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalBlood advances
Issue number1
StatePublished - 11 Jan 2022


FundersFunder number
Amgen Limited
Austrian Science Found I 1576
Novartis Pharmacy B.V. Oncology Europe
Verein Senioren-Krebshilfe
Gilead Sciences
Takeda Pharmaceutical Company
Janssen Pharmaceuticals
European Commission
Horizon 2020634789


    Dive into the research topics of 'Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists'. Together they form a unique fingerprint.

    Cite this